Quintrio
Home

Stock overview

Jyong Biotech Ltd. Ordinary Shares

MENS

Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.63 – $1.82
Volume 13,608
Market cap $131M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for MENS.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for MENS.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships

Jyong Biotech reaffirms its strategic focus on global licensing partnerships to address the growing BPH market. The company highlights that the global BPH patient population reached 112.5 million in 2021 and is projected to grow to 150-156 million by 2035, with the market size expected to grow from $13 billion in 2025 to $22-22.6 billion by 2035. Jyong Biotech's lead candidate Botreso® (API-1) has completed four Phase III clinical trials and aims to address unmet medical needs caused by severe side effects of existing treatments.

Benzinga

Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%

The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.